Social Survey Research Information Co., Ltd.
NEWS
Social Survey Research Information Co., Ltd.
PatientsMap analysis of Chinese physicians’ needs for new drugs
Overall, lifestyle-related diseases such as hypertension, which are treated by many physicians, rank at the top.
Physicians treating the respective conditions had strong needs for new cancer drugs.
Social Survey Research Information Co., Ltd. and M3, Inc. conducted an analysis of new drug needs in China using data from PatientsMap 2022CN (China 2022 version).
The data were obtained from a survey of member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company, with 11,106 physicians responding.
Looking at the needs for new drugs based on all the physicians who responded (Table 1), hypertension ranked the highest at 29.5%, which was followed by dyslipidemia at 25.0% and diabetes at 22.7%, indicating that lifestyle-related diseases, which account for a high percentage of medical care, are at the top of the list. While new drug needs for dementia and obesity are at the top in Japan and the U.S., respectively, the results indicate that the need for new drugs for lifestyle-related diseases is still strong in China.
Meanwhile, the top five conditions for which physicians would like new drugs were analyzed among all conditions, conditions that have physician coverage (percentage of physicians who treat the conditions) of at least 1%, and conditions that have physician coverage of at least 5% (Table 2). Among all conditions, Canavan disease, which has extremely low (0.01%) physician coverage, and HTLV-1 associated myelopathy (HAM), which has physician coverage of 0.05%, ranked at the top.
Meanwhile, the top conditions in terms of new drug needs among those that have physician coverage of at least 1% and 5% are all cancers, indicating there is strong demand for cancer drugs. The results also showed that there is strong demand for new drugs for AML, ALL, cholangiocellular carcinoma, pancreatic cancer, and small cell lung cancer.
In China, as in Japan and the U.S., there is a strong need for new drugs for various hematologic and solid cancers.
The results also suggest that the top diseases in terms of physician need on the whole and by physicians who treat the respective conditions differ greatly in terms of the physician coverage, and that the dissemination methods for new drugs for lifestyle-related diseases, for which the market is large, are completely different from those for new cancer drugs.
Rank | TOTAL | ||
---|---|---|---|
Condition | Physician coverage | % of physicians who want new drugs | |
1 | Hypertension | 69.4% | 29.5% |
2 | Dyslipidemia | 59.1% | 25.0% |
3 | Diabetes | 66.2% | 22.7% |
4 | Type 2 Diabetes | 64.9% | 22.3% |
5 | COPD | 41.0% | 20.2% |
6 | Atrial fibrillation | 43.8% | 20.2% |
7 | Cerebral infarction | 44.1% | 19.3% |
8 | Hypertriglyceridemia | 58.3% | 17.9% |
9 | Constipation | 42.8% | 15.8% |
10 | Bronchial asthma | 32.2% | 15.7% |
Rank | TOTAL | ||
---|---|---|---|
Condition | Physician coverage | % of physicians who want new drugs | |
1 | Canavan disease | 0.01% | 100.00% |
2 | HTLV-1 associated myelopathy (HAM) | 0.05% | 80.00% |
3 | Acute myeloid leukemia (AML) | 3.91% | 79.00% |
4 | Post-transplant thrombotic microangiopathy | 0.20% | 77.30% |
5 | Acute lymphoid leukemia (ALL) | 3.93% | 74.10% |
Rank | Physician coverage of at least 1% | Physician coverage of at least 5% | ||||
---|---|---|---|---|---|---|
Condition | Physician coverage | % of physicians who want new drugs | Condition | Physician coverage | % of physicians who want new drugs | |
1 | Acute myeloid leukemia (AML) | 3.90% | 79.00% | Cholangiocellular carcinoma | 5.20% | 70.60% |
2 | Acute lymphoid leukemia (ALL) | 3.90% | 74.10% | Pancreatic cancer | 7.90% | 69.60% |
3 | Cholangiocellular carcinoma | 5.20% | 70.60% | Small cell lung cancer | 13.20% | 68.70% |
4 | Pancreatic cancer | 7.90% | 69.60% | Hepatocellular carcinoma | 13.40% | 68.50% |
5 | Small cell lung cancer | 13.20% | 68.70% | Biliary tract cancer | 6.60% | 67.10% |
Outline of PatientsMap 2022CN
Condition coverage: 402 conditions
Target respondents: Medlive.cn-registered physicians
Inclusion criteria: Physicians of all specialties at hospitals and clinics
Method: Online survey
Number of cooperating physicians: 11,106
Fieldwork period: December 27, 2021 to March 4, 2022
Survey topic: Conditions seen
Number of patients seen
Number of patients who were prescribed drugs
Conditions for which new drugs are desired
Sales rep visits
In Japan, this service will be jointly provided by Social Survey Research Information Co., Ltd. and M3, Inc.
■ Contact Information
Social Survey Research Information Co., Ltd.
E-mail: patientsmap@ssri.com
■ Social Survey Research Information Co., Ltd.
Established: April 1982
Capital: 27 million JPY
President & CEO: Takashi Makita
Number of employees: 137
Location: Head Office
NMF Shinjuku East Bldg. 2F, 3F
10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN
Osaka office:
Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046
Affiliate companies: PD Research Co., Ltd.
MDB Co.
SSRI China Co., Ltd. (overseas subsidiary)
SSRI Asia Pacific Co., Ltd. (overseas subsidiary)
HIMA Research (overseas affiliate)
URL: http://www.ssri.com/
■ M3, Inc.
Established: September 2000
Capital: 29.036 billion JPY (as of March 31, 2021)
Representative Director: Itaru Tanimura
Number of employees, consolidated: 8,249 (as of March 31, 2021)
Location: Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo
URL: https://corporate.m3.com/